Scarica l'app Stockscreener
22.83
1.28%
-0.27
Precedente Chiudi:
$23.10
Aprire:
$23.2
Volume 24 ore:
92,179
Relative Volume:
0.08
Capitalizzazione di mercato:
$2.00B
Reddito:
$23.38M
Utile/perdita netta:
$-155.22M
Rapporto P/E:
-10.42
EPS:
-2.19
Flusso di cassa netto:
$-134.36M
1 W Prestazione:
-8.78%
1M Prestazione:
+1.45%
6M Prestazione:
+6.67%
1 anno Prestazione:
-39.81%
Intervallo 1D:
$22.69
$23.27
Intervallo di 1 settimana:
$22.09
$25.82
Portata 52W:
$13.45
$40.74
Ideaya Biosciences Inc Stock (IDYA) Company Profile
Nome
Ideaya Biosciences Inc
Settore
Industria
Telefono
650-443-6209
Indirizzo
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
Confronta IDYA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IDYA
Ideaya Biosciences Inc
|
22.80 | 2.07B | 23.38M | -155.22M | -134.36M | -2.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
378.18 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.54 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
642.06 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.70 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-22 | Iniziato | TD Cowen | Buy |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-06-26 | Iniziato | Wells Fargo | Overweight |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-11-05 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2024-03-08 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | SVB Securities | Outperform |
| 2023-05-24 | Iniziato | Goldman | Buy |
| 2023-04-24 | Aggiornamento | Stifel | Hold → Buy |
| 2023-03-23 | Iniziato | Berenberg | Buy |
| 2023-02-28 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-12-28 | Iniziato | CapitalOne | Overweight |
| 2022-10-27 | Iniziato | Citigroup | Buy |
| 2022-08-15 | Downgrade | Stifel | Buy → Hold |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-10 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-23 | Iniziato | Stifel | Hold |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-03-11 | Iniziato | Guggenheim | Buy |
| 2020-10-07 | Iniziato | Wedbush | Outperform |
| 2020-09-01 | Iniziato | Northland Capital | Outperform |
| 2020-07-13 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-06-17 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-06 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-13 | Iniziato | ROTH Capital | Buy |
| 2019-10-17 | Iniziato | Oppenheimer | Outperform |
| 2019-09-10 | Iniziato | Robert W. Baird | Outperform |
| 2019-06-17 | Iniziato | Citigroup | Buy |
| 2019-06-17 | Iniziato | JP Morgan | Neutral |
| 2019-06-17 | Iniziato | Jefferies | Buy |
Mostra tutto
Ideaya Biosciences Inc Borsa (IDYA) Ultime notizie
GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer? - TipRanks
IDEAYA Biosciences: Hold Rating Amid Key Pipeline Developments and Anticipated Clinical Milestones - TipRanks
RBC Capital Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $30 - 富途牛牛
Ideaya Biosciences, Hengrui announce oral presentation at IASLC 2025 - MSN
IDEAYA Biosciences Inc Reports Q2 2025 Financial Results: Net Loss of $77.5 Million, EPS of -$0.88, and No Revenue - AInvest
Ideaya Biosciences Q2 EPS Beats Consensus, Sees Catalyst-Rich Period Ahead - AInvest
GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959 - TipRanks
Ideaya Biosciences shares rise 3.19% premarket after reporting Q2 net loss and positive trial data. - AInvest
IDEAYA Biosciences Reports Q2 2025 Financial Results - TipRanks
IDEAYA (IDYA) Q2 Net Loss Improves 27% - The Motley Fool
IDEAYA (IDYA) Q2 Net Loss Improves 27% - Nasdaq
IDEAYA Biosciences Enters ADC Market with Solid Tumor Focus - AInvest
IDEAYA Biosciences: Moving Into ADCs For Solid Tumors (NASDAQ:IDYA) - Seeking Alpha
Ideaya Biosciences earnings missed by $0.09, revenue topped estimates - Investing.com
IDEAYA Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
IDEAYA Biosciences Reports Q2 GAAP EPS of -$0.88, Misses Expectations - AInvest
IDEAYA Biosciences's Q2 net loss widens as costs mount - MarketScreener
IDEAYA Reports Phase 2/3 Trial Data and Neoadjuvant Darovasertib Results - AInvest
IDEAYA Advances 6 Clinical Programs, Reports Massive $992M Cash Runway Through 2029 - Stock Titan
IDEAYA Biosciences, Inc. Reports Second Quarter 2025 Financial Results and Provides Business Update - Ariva
Published on: 2025-08-05 04:17:11 - metal.it
Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study - TipRanks
Ideaya Biosciences shares rise 6.02% premarket as New Zealand shares down tracking Wall Street sell-off. - AInvest
What institutional investors are buying IDEAYA Biosciences Inc. stockCapitalize on proven trading setups - Jammu Links News
How many analysts rate IDEAYA Biosciences Inc. as a “Buy”Maximize portfolio growth with expert advice - Jammu Links News
How does IDEAYA Biosciences Inc. compare to its industry peersConsistent triple-digit returns - Jammu Links News
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - cnhinews.com
What analysts say about IDEAYA Biosciences Inc. stockGet expert advice on portfolio optimization - Jammu Links News
Should I hold or sell IDEAYA Biosciences Inc. stock in 2025Unlock powerful portfolio management tools - Jammu Links News
What makes IDEAYA Biosciences Inc. stock price move sharplyInvest smarter with daily market updates - Jammu Links News
What drives IDEAYA Biosciences Inc. stock priceMaximize gains with strategic stock entries - Jammu Links News
What is the risk reward ratio of investing in IDEAYA Biosciences Inc. stockGet alerts on the hottest stocks daily - Jammu Links News
How strong is IDEAYA Biosciences Inc. company’s balance sheetMarket-crushing stock picks - Jammu Links News
What catalysts could drive IDEAYA Biosciences Inc. stock higher in 2025Unlock expert stock analysis and alerts - Jammu Links News
How sentiment analysis helps forecast IDEAYA Biosciences Inc.Neural Network Based Equity Prediction System - Newser
IDEAYA Biosciences Awards Stock Options to New Employee - AInvest
Historical volatility pattern of IDEAYA Biosciences Inc. visualizedIntraday Signal Forecast for Fast Traders - Newser
IDEAYA Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
IDEAYA Biosciences Awards $765K Worth of Stock Options to New Employee: Full Grant Details - Stock Titan
How to build a custom watchlist for IDEAYA Biosciences Inc.Consistent Gain Plan with AI Support - Newser
TD Cowen Bullish on Ideaya’s (IDYA) Oncology Pipeline - MSN
What is IDEAYA Biosciences Inc. company’s growth strategyPost Market Review For 2025 - jammulinksnews.com
Mizuho lowers Ideaya Biosciences stock price target to $43 on pipeline review - Investing.com Canada
Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $43 - 富途牛牛
Mizuho Securities Maintains Buy Rating and $43 Price Target for IDEAYA Biosciences (IDYA) - AInvest
Will IDEAYA Biosciences Inc. bounce back from current supportRisk-Managed Swing Setup and Signal Analysis - Newser
Is IDEAYA Biosciences Inc. Stock a Smart Buy in 2025 Investment Analysis Inside - metal.it
Applying Wyckoff theory to IDEAYA Biosciences Inc. stockSwing Setup With Technical Confirmation Explained - metal.it
Chart based analysis of IDEAYA Biosciences Inc. trendsAsset Allocation Summary With Future Outlook - Newser
Will IDEAYA Biosciences Inc. outperform the marketNext Day Momentum Stock Forecasting Report - Newser
Why IDEAYA Biosciences Inc. stock attracts strong analyst attentionFree Proven Entry Plan With Low Risk Trade - Newser
Ideaya Biosciences Inc Azioni (IDYA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.98%
1.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):